

The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²

¹*Department of Medical Laboratory Science, Kampala International University, Uganda.*

²*School of Nursing Science, Kampala International University, Uganda.*

*Corresponding author: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, \[emmanuelobeagu@yahoo.com\]\(mailto:emmanuelobeagu@yahoo.com\), ORCID: 0000-0002-4538-0161](#)

Abstract

The coexistence of Human Immunodeficiency Virus (HIV) and anemia presents a multifaceted challenge in patient management. Anemia, prevalent in individuals with HIV, stems from diverse etiologies, including direct viral impact, medication side effects, and opportunistic infections. Blood transfusion strategies have emerged as crucial interventions to alleviate severe anemia-related symptoms; however, their optimal utilization in the context of HIV management remains an area of ongoing exploration. This comprehensive review delves into the current insights surrounding the role of blood transfusion strategies in HIV management, encompassing epidemiology, benefits, risks, immunomodulatory effects, and their influence on patient outcomes. The prevalence and etiology of anemia in individuals with HIV are discussed, emphasizing the need for personalized and multidisciplinary approaches to address this complex comorbidity. By synthesizing current knowledge and identifying avenues for future investigation, this review aims to contribute to evidence-based practices, ultimately improving the care and outcomes for individuals navigating the complexities of HIV infection and anemia.

Keywords: *Blood Transfusion, HIV, Transfusion Therapy, Anemia, Antiretroviral Therapy, Immunomodulation, Patient Outcomes, Future Directions*

Introduction

The intersection of Human Immunodeficiency Virus (HIV) infection and anemia represents a complex healthcare challenge with profound implications for individuals' well-being. While advancements in antiretroviral therapy (ART) have significantly improved the prognosis and quality of life for those living with HIV, anemia remains a prevalent and multifactorial

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

complication. The coexistence of HIV and anemia necessitates a nuanced approach to patient management, and blood transfusion strategies have emerged as pivotal interventions to address severe anemia and its associated symptoms.¹⁻¹⁶ HIV infection has undergone a transformative evolution since its discovery, evolving from a once-debilitating and often fatal disease to a manageable chronic condition with appropriate medical intervention. Despite these strides, anemia continues to exert a substantial impact on the health and well-being of individuals living with HIV. The etiology of anemia in this population is diverse, ranging from the virus's direct effects on hematopoiesis to the adverse consequences of antiretroviral medications and the presence of opportunistic infections.¹⁷⁻³⁰

The rationale for exploring the role of blood transfusion strategies in HIV management stems from the intricate relationship between anemia and the viral infection. Anemia not only poses immediate challenges related to fatigue, impaired oxygen-carrying capacity, and diminished quality of life but may also have implications for the overall course of HIV disease. Blood transfusions offer a rapid and effective means of addressing severe anemia, yet their optimal use within the broader context of HIV management requires careful consideration of potential risks and benefits.

Prevalence and Etiology of Anemia in HIV

Anemia is a pervasive hematological complication in individuals living with Human Immunodeficiency Virus (HIV), contributing to a significant burden on their overall health. The prevalence of anemia in this population varies across geographic regions, disease stages, and demographic factors. Studies have reported anemia rates ranging from 20% to 70%, with a higher prevalence observed in advanced stages of HIV and among specific demographic groups. The epidemiology of anemia in HIV is influenced by multifactorial determinants, including the stage of the disease, gender, age, socioeconomic factors, and the availability of antiretroviral therapy (ART). As individuals with HIV are now living longer due to effective ART, the impact of aging and long-term antiretroviral use on anemia prevalence is an area of ongoing research. The etiology of anemia in HIV is complex and often multifaceted, involving a combination of HIV-related factors, medication side effects, and comorbid conditions.³¹⁻⁴⁵

HIV can directly affect hematopoiesis by infecting and damaging bone marrow progenitor cells, leading to decreased production of red blood cells. This direct viral impact contributes to the development of anemia, particularly in individuals with advanced HIV disease. Antiretroviral medications, while crucial for controlling viral replication, may have hematological side effects. Certain classes of antiretrovirals, such as zidovudine, have been associated with bone marrow suppression and anemia. Management strategies involve balancing the benefits of viral suppression with the potential hematologic consequences. HIV-infected individuals are susceptible to opportunistic infections that can contribute to anemia. Mycobacterial and fungal infections, including *Mycobacterium avium* complex and *Cryptococcus*, may directly affect hematopoiesis or lead to chronic inflammation, exacerbating anemia.⁴⁶⁻⁵⁵

Malnutrition and micronutrient deficiencies, such as iron, vitamin B12, and folate, are common in individuals with HIV and can contribute to the development of anemia. The interplay between

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

nutritional status and anemia underscores the importance of comprehensive care and nutritional support. Chronic immune activation and inflammation associated with HIV infection contribute to the development of anemia. Inflammatory cytokines, such as interleukin-6, can interfere with erythropoiesis and lead to the sequestration of iron in macrophages, further exacerbating anemia. HIV infection is associated with an increased risk of hemolysis and coagulation disorders, which can contribute to anemia. Conditions such as immune thrombocytopenic purpura and thrombotic microangiopathy may coexist with HIV and impact red blood cell production and survival.⁵⁶⁻⁶³

Blood Transfusion Strategies in HIV Management

Blood transfusions play a pivotal role in managing severe anemia in individuals living with Human Immunodeficiency Virus (HIV). The decision to initiate a blood transfusion is guided by various clinical indicators, including symptomatic anemia, a significant decline in hemoglobin levels below predefined thresholds, and acute exacerbations of anemia-related symptoms. The goal is to alleviate immediate symptoms, improve oxygen-carrying capacity, and address potential life-threatening complications associated with severe anemia.⁶⁴⁻⁷¹

The threshold for transfusion may vary based on individual patient factors, the presence of comorbidities, and the overall clinical context. Common indications include hemoglobin levels below 7-8 g/dL in stable patients and higher thresholds in the presence of acute complications or comorbidities. Blood transfusions offer rapid and effective relief from severe anemia-related symptoms, providing an immediate increase in hemoglobin levels. The benefits of transfusions extend beyond symptomatic relief and include: Transfusions enhance the oxygen-carrying capacity of the blood, alleviating symptoms such as fatigue, dyspnea, and exercise intolerance. In severe cases, anemia can lead to organ dysfunction. Blood transfusions help prevent or mitigate the impact of anemia on vital organs, particularly the heart and brain. In acute scenarios, such as active bleeding or rapid-onset severe anemia, blood transfusions can be life-saving, providing essential support until the underlying cause is addressed. While blood transfusions offer significant benefits, they are not without risks and considerations, especially in the context of HIV management: Adverse reactions to transfusions, including hemolytic reactions, febrile reactions, and allergic responses, are potential risks. Vigilant monitoring and compatibility testing are essential to minimize these risks.⁷²⁻⁷³

The transmission of infectious agents, including HIV, hepatitis B and C, and other blood-borne pathogens, is a concern. Rigorous screening and testing of donated blood have significantly reduced the risk of transmission but remain considerations. Individuals receiving multiple transfusions may be at risk of iron overload, leading to complications such as hemochromatosis. Regular monitoring of iron levels and appropriate iron-chelation therapy are crucial in managing this risk. The impact of blood transfusions on HIV viral load and immune function is an area of ongoing research and consideration. Studies have suggested transient increases in viral load post-transfusion, emphasizing the need for careful monitoring.⁷⁴⁻⁷⁵ Blood transfusions may have immunomodulatory effects, potentially influencing the recipient's immune function. This is particularly relevant in the context of HIV, where immune compromise is inherent.

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*, 2024; 2(1):10-22

Immunomodulatory Effects of Blood Transfusions

Blood transfusions, while primarily aimed at addressing anemia-related symptoms, have been associated with immunomodulatory effects, potentially influencing both the innate and adaptive immune systems. In the context of individuals living with Human Immunodeficiency Virus (HIV), understanding these immunomodulatory effects is critical, given the pre-existing immune compromise inherent in HIV infection.⁷⁶ The transfusion of allogeneic blood introduces foreign antigens to the recipient's immune system. This exposure can trigger immune responses and modulate the function of immune cells, including T cells, B cells, and antigen-presenting cells. Studies have shown alterations in cytokine profiles and immune cell activation following blood transfusions, suggesting a potential impact on the recipient's immune response. A concept known as "transfusion-related immunomodulation" (TRIM) proposes that blood transfusions may induce a state of temporary immunosuppression in recipients. This immunosuppression is characterized by decreased immune cell responsiveness and impaired host defenses against infections. While the exact mechanisms are not fully elucidated, factors such as donor leukocytes, cytokines, and other bioactive substances in transfused blood may contribute to TRIM. In the context of HIV, where maintaining optimal immune function is paramount, the potential immunomodulatory effects of blood transfusions raise important considerations. Individuals with HIV already experience compromised immune function due to the direct impact of the virus on CD4+ T cells and other immune components. Therefore, understanding how blood transfusions may interact with the existing immune milieu in HIV-infected individuals is crucial for optimizing patient outcomes.

Influence of Blood Transfusions on Patient Outcomes

The influence of blood transfusions on the quality of life in individuals with HIV and anemia is a complex interplay of physiological improvements and potential complications.⁷⁷ While transfusions provide symptomatic relief and enhance overall well-being, the associated risks and considerations, including the impact on immune function, must be carefully weighed. Long-term health outcomes following blood transfusions in individuals with HIV remain an area of active investigation. The potential implications for viral control, immune function, and the development of complications such as iron overload warrant ongoing research. Longitudinal studies assessing the impact of transfusions on morbidity and mortality in this population are essential for shaping evidence-based clinical practices.

Future Directions

Blood transfusions play a significant role in improving the immediate symptoms of severe anemia, thereby enhancing the quality of life for individuals living with Human Immunodeficiency Virus (HIV).⁷⁸ Symptomatic relief, including decreased fatigue, improved exercise tolerance, and relief from dyspnea, contributes to an overall improvement in the daily functioning and well-being of recipients. The impact on quality of life extends beyond the physiological benefits to encompass psychosocial aspects. Individuals experiencing the debilitating effects of severe anemia often face challenges in performing routine activities and may grapple with emotional distress. Blood transfusions provide a rapid and tangible improvement in these aspects, positively influencing the

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

mental and emotional well-being of recipients. While blood transfusions offer immediate relief, their influence on long-term health outcomes in individuals with HIV is a complex interplay of benefits and potential risks. Several factors contribute to the considerations of long-term health outcomes:

The immunomodulatory effects of transfusions may have implications for long-term immune function. Understanding how transfusions interact with the immune system in individuals with HIV is crucial for assessing their influence on disease progression and susceptibility to opportunistic infections. Long-term health outcomes are influenced by potential complications associated with blood transfusions, such as iron overload and the transmission of infectious agents. Regular monitoring and appropriate interventions are essential for managing these risks. The integration of blood transfusions with antiretroviral therapy (ART) is a critical aspect of long-term HIV management. Considering potential interactions between transfusions and antiretroviral medications is essential for optimizing overall treatment strategies.

Psychosocial considerations are integral to assessing the influence of blood transfusions on patient outcomes. Individuals living with HIV often navigate complex emotional and social challenges, and severe anemia can exacerbate these difficulties. Blood transfusions provide not only physical relief but also address the emotional toll associated with chronic illness. Psychosocial support, including counseling and education, is crucial in the context of blood transfusions. Addressing concerns related to the procedure, potential complications, and the broader impact on daily life fosters resilience and empowers individuals to actively engage in their healthcare journey.

The influence of blood transfusions on patient outcomes underscores the importance of a holistic, patient-centered approach in HIV management. Collaboration among healthcare professionals from various specialties, including hematologists, infectious disease specialists, and mental health professionals, is essential. This interdisciplinary approach ensures that the physical, emotional, and social dimensions of care are addressed comprehensively. Future research should focus on longitudinal studies assessing the impact of blood transfusions on morbidity, mortality, and overall quality of life in individuals with HIV. Investigating the specific factors that contribute to long-term health outcomes, including the interplay with viral load dynamics and immune function, will further refine evidence-based practices.

Conclusion

The role of blood transfusion strategies in the comprehensive management of individuals living with Human Immunodeficiency Virus (HIV) and anemia is intricate and multifaceted. This review has provided a comprehensive exploration of the prevalence and etiology of anemia in the context of HIV, the indications and benefits of blood transfusions, and the potential risks and immunomodulatory effects associated with this intervention. Additionally, we have delved into the influence of blood transfusions on patient outcomes, encompassing quality of life, long-term health considerations, and psychosocial aspects. The prevalence of anemia in individuals with HIV, influenced by factors such as direct viral impact, medication side effects, opportunistic infections, and nutritional deficiencies, highlights the need for personalized and multidisciplinary

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*, 2024; 2(1):10-22

approaches to address this complex comorbidity. Blood transfusions emerge as crucial interventions to alleviate severe anemia-related symptoms, providing immediate relief and improving the overall quality of life for recipients.

While the benefits of blood transfusions are evident, the potential risks, including transfusion reactions, infectious transmission, and immunomodulatory effects, necessitate careful consideration in the context of HIV management. Balancing the benefits and risks requires a personalized and multidisciplinary approach, with close collaboration among healthcare professionals to optimize patient outcomes. The immunomodulatory effects of blood transfusions, particularly in the context of HIV, present a complex landscape of interactions between the transfused blood and the recipient's immune system. Understanding these effects is crucial for tailoring transfusion strategies and optimizing long-term health outcomes for individuals living with HIV. The influence of blood transfusions on patient outcomes extends beyond the physiological realm to encompass psychosocial considerations. Addressing the psychosocial aspects of care, including counseling, education, and emotional support, is integral to a holistic and patient-centered approach.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 1-5.DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*, 2024; 2(1):10-22

8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.1007/s12245-022-129-1).
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International. 2021;33(52B):10-19.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International. 2021;33(4):10-19.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. Journal of Pharmaceutical Research International. 2020;32(22):101-119.
12. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.1007/s12245-016-129-1).
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. International Journal of Current Microbiology and Applied Sciences. 2015;4(4):911-916.
https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. Int. J. Adv. Res. Biol. Sci. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.1007/s12245-017-129-1)
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. Madonna University journal of Medicine and Health Sciences. 2022;2(3):110-119.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. Nigeria. J. Bio. Innov. 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.1007/s12245-016-129-1).

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. J Pub Health Nutri. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://epjournals.com/journals/EJM/links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf).
19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. Int J Curr Res Aca Rev. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf.
20. Obimah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://epjournals.com/journals/EJM/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
23. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://epjournals.com/journals/EJM/links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
24. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
25. Walter O, Anaabo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022;29-34.
26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://epjournals.com/journals/EJM/links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf).

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):135-142.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://www.research.sdpublishers.net/id/eprint/2819/links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://www.research.sdpublishers.net/id/eprint/2819/links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf)
30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014) https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf
31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
32. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences.* 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
33. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: **DOI:** [10.32474/JCCM.2020.02.000137](https://doi.org/10.32474/JCCM.2020.02.000137) [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://www.research.sdpublishers.net/id/eprint/2819/links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf)
34. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
35. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
36. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at

- Citation:** Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. Elite Journal of Medicine, 2024; 2(1):10-22

47. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
48. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):28-31.
49. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review. Newport International Journal of Public Health and Pharmacy (NIJPP)*. 2023;3(2):64-67.
50. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
51. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
52. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parametrs in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
53. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research.* 2014; 391:186-189.
54. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3 (1): 7-12.
55. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
56. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutiase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences.* 2015;2(11):268-271.
57. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickel Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-59.
58. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
59. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.

Citation: Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*, 2024; 2(1):10-22

60. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord.* 2018;1(2).
61. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
62. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-19.
63. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
64. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
65. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
66. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore).* 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
67. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore).* 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
68. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep.* 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
69. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS).* 2023;3(3).
70. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
71. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.

72. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sick Cell Anaemia. Newport International Journal of Scientific and Experimental Sciences (NIJSES). 2023;3(2):56-9.
73. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023;11(10):01-6.
74. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
75. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood, The Journal of the American Society of Hematology. 2019;133(17):1854-64.
76. Ward AR, Mota TM, Jones RB. Immunological approaches to HIV cure. In Seminars in immunology 2021; 51: 101412). Academic Press.
77. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. APPLIED SCIENCES (NIJBAS). 2023;3(3).
78. Taher AT, Bou-Fakhredin R, Kattamis A, Viprakasit V, Cappellini MD. Improving outcomes and quality of life for patients with transfusion-dependent β -thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Review of Hematology. 2021;14(10):897-909.